Amgen (NASDAQ: AMGN) has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval of BLINCYTO (blinatumomab) for the consolidation phase treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL), irrespective of measurable residual disease (MRD) status. Key Study Findings […]
In a significant development in chronic obstructive pulmonary disease (COPD) management, the Phase IIa COURSE trial, a proof-of-concept study led by AstraZeneca in partnership with Amgen, has revealed key findings about TEZSPIRE (tezepelumab) and its effects on COPD exacerbations. Despite a non-statistically significant overall reduction, a notable subgroup analysis showed potential benefits for patients with […]
Amgen (NASDAQ: AMGN), a global biotechnology leader, has announced its plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab. This treatment, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), is aimed at adults suffering from moderate to severe Thyroid Eye Disease […]
Quantinuum, a global leader in integrated quantum computing, has announced the closing of a substantial $300 million equity fundraise. This financial milestone, achieved at a pre-money valuation of $5 billion, is anchored by strategic partner JPMorgan Chase, along with contributions from Mitsui & Co., Amgen, and Honeywell, which continues to be the company’s majority shareholder. […]
Glenmark Pharmaceuticals Ltd. has successfully secured the final approval from the United States Food & Drug Administration (U.S. FDA) for its Apremilast Tablets in 10 mg, 20 mg, and 30 mg dosages. This approval allows Glenmark to market the generic counterpart of Amgen Inc.’s Otezla Tablets. Recent IQVIA sales figures reveal that the market for […]
Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise value of around $28.3bn. The US biotechnology company will pay $116.5 per share in cash, which is a premium of around 19.7% to Horizon Therapeutics’ closing stock price of $97.29 per share on 9 December 2022. Horizon […]
Amgen has agreed to acquire ChemoCentryx, a biopharma company engaged in developing medications for inflammatory and autoimmune diseases and cancer, in an all-cash deal worth around $3.7 billion. Based in California, ChemoCentryx is listed on NASDAQ. As per the terms of the deal, its shareholders will be offered $52 per share. Through the deal, Amgen […]
Liberty Mutual Insurance has wrapped up the previously announced MYR 2.29 billion ($515 million) acquisition of AmGeneral Insurance Berhad, a Malaysian insurer, having secured regulatory approval in Malaysia and signed a purchase and sale deal with AmBank Group. The deal was announced in July 2021 and executed by Liberty Mutual Insurance’s subsidiary — Liberty Insurance […]
Amgen has signed a research collaboration deal worth up to $1.9 billion with Cambridge-based Generate Biomedicines for the discovery and development of protein therapeutics for five clinical targets across various therapeutic areas and multiple modalities by leveraging the latter’s machine learning-enabled technology platform. Under the terms of the research collaboration deal, Amgen will make an […]
LUMAKRAS FDA approval : Amgen has bagged accelerated approval from the US Food and Drug Administration (FDA) for LUMAKRAS (sotorasib) for the treatment of a type of non-small cell lung cancer (NSCLC) in adults. The approval is for the treatment of patients whose cancer is locally advanced or metastatic and have KRAS G12C mutation, as […]